炔诺酮

**炔诺酮**
系统（IUPAC）命名名称
	(8R,9S,10R,13S,14S,17R)-17-ethynyl-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
临床数据
商品名	Alone: Aygestin, Camila, Heather, Micronor, Primolut N, others; With EE: Lo Loestrin, Loestrin, Microgestin, Modicon, Norinyl, Ortho-Novum, others; With E2: Activella, Activelle, Estalis, Kliogest, Necon, Novofem, Trisequens, others
Drugs.com	国际药品名称
MedlinePlus	a604034
给药途径	By mouth, intramuscular injection (as NETE)
药代动力学数据
生物利用度	47–73% (mean 64%)
蛋白结合度	97%:; Albumin: 61%;; SHBG: 36%
代谢	Mainly CYP3A4 (liver); also 5α-/5β-reductase, 3α-/3β-HSD, and aromatase
生物半衰期	5.2–12.8 hours (mean 8.0 hours)
识别信息
CAS注册号	68-22-4
ATC代码	G03AC01 G03DC02
PubChem	CID 6230
IUPHAR/BPS（英语：IUPHAR/BPS）	2880
DrugBank	DB00717
ChemSpider	5994
UNII	T18F433X4S
KEGG	D00182
ChEBI	CHEBI:7627
ChEMBL（英语：ChEMBL）	CHEMBL1162
其他名称	NET; Norethindrone; NSC-9564; LG-202; Ethinylnortestosterone; Norpregneninolone; Anhydrohydroxy-norprogesterone; Ethinylestrenolone; 17α-Ethynyl-19-nortestosterone; 17α-Ethynylestra-4-en-17β-ol-3-one; 17α-Hydroxy-19-norpregn-4-en-20-yn-3-one
化学信息
化学式	C20H26O2
摩尔质量	298.419 g/mol
	SMILES C[[email protected]]12CC[[email protected]]3[[email protected]]([[email protected]@H]1CC[[email protected]]2(C#C)O)CCC4=CC(=O)CC[[email protected]]34; ;
	InChI InChI=1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,15-18,22H,4-11H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1 ; Key:VIKNJXKGJWUCNN-XGXHKTLJSA-N ;
物理性质
熔点	203至204 °C（397至399 °F）

Error in template * unknown parameter name (Template:Infobox_drug): 'class' （參見參數列表（英语：Template:Infobox drug/doc/full parameter list）。）

此錯誤不會顯示於內文之中，僅會在預覽時顯示。

炔诺酮（英語：Norethisterone 或英語：norethindrone）是一种黄体制剂药物，用做口服避孕药和激素替代療法药物以及治疗一些妇科疾病^[4]。

^ ^1.0 ^1.1 Stanczyk, Frank Z. Pharmacokinetics and Potency of Progestins used for Hormone Replacement Therapy and Contraception (PDF). Reviews in Endocrine and Metabolic Disorders. Sep 2002, 3 (3): 211–224. ISSN 1389-9155. PMID 12215716. doi:10.1023/A:1020072325818.
^ Fotherby K. Bioavailability of orally administered sex steroids used in oral contraception and hormone replacement therapy. Contraception. August 1996, 54 (2): 59–69. PMID 8842581. doi:10.1016/0010-7824(96)00136-9.
^ Korhonen T, Turpeinen M, Tolonen A, Laine K, Pelkonen O. Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. J. Steroid Biochem. Mol. Biol. 2008, 110 (1–2): 56–66. PMID 18356043. doi:10.1016/j.jsbmb.2007.09.025.
^ Kathryn Rhodes Alden; Deitra Leonard Lowdermilk; Mary Catherine Cashion; Shannon E. Perry. Maternity and Women's Health Care - E-Book. Elsevier Health Sciences. 27 December 2013: 135–. ISBN 978-0-323-29368-6.

[pmid12215716-1] 1.0 ^1.1 Stanczyk, Frank Z. Pharmacokinetics and Potency of Progestins used for Hormone Replacement Therapy and Contraception (PDF). Reviews in Endocrine and Metabolic Disorders. Sep 2002, 3 (3): 211–224. ISSN 1389-9155. PMID 12215716. doi:10.1023/A:1020072325818.

[pmid8842581-2] Fotherby K. Bioavailability of orally administered sex steroids used in oral contraception and hormone replacement therapy. Contraception. August 1996, 54 (2): 59–69. PMID 8842581. doi:10.1016/0010-7824(96)00136-9.

[pmid18356043-3] Korhonen T, Turpeinen M, Tolonen A, Laine K, Pelkonen O. Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. J. Steroid Biochem. Mol. Biol. 2008, 110 (1–2): 56–66. PMID 18356043. doi:10.1016/j.jsbmb.2007.09.025.

[AldenLowdermilk2013-4] Kathryn Rhodes Alden; Deitra Leonard Lowdermilk; Mary Catherine Cashion; Shannon E. Perry. Maternity and Women's Health Care - E-Book. Elsevier Health Sciences. 27 December 2013: 135–. ISBN 978-0-323-29368-6.

[1]

[2]

[3]

[4]

炔诺酮 转为简体

炔诺酮